GYN ONCOLOGY
ROTATION INFORMATION
What is Gynecologic Oncology (Gyn-Onc)?

Gynecologic Oncology is a subspecialty of Ob-Gyn. The other two Ob-Gyn subspecialties are Maternal Fetal Medicine (High risk Obstetrics, MFM) and Reproductive Medicine (Endocrine and Infertility). Certification in Gyn-Onc requires training and board certification in Ob-Gyn and then 2-4 years of fellowship training in Gyn-Onc. Gynecology Oncologists are involved in the diagnosis, staging, treatment and follow-up of women with cancer of the female reproductive tract. Gynecology Oncologists manage new cancers, recurrences, complications, and end of life care. Unlike other oncology disciplines, Gyn-Onc deals with all treatment modalities in a specialized area rather one modality for the entire body such as Medical Oncology and Radiation Oncology. Gynecology Oncologists are versed in surgery, radiation therapy, and chemotherapy. Most Gynecology Oncologists do not manage breast cancer.

What we expect in a week on the Gynecologic Oncology Service:

At the end of this week you should know what diseases are managed by Gyn-Onc and have some familiarity with gynecology cancer diagnosis, staging, and treatment. Regardless of what area of medicine you eventually go into, we want you to know who to call if you encounter a patient with a suspected gynecology cancer problem. We do not expect you to become an expert in gynecology cancer, but as a result of your experience, we do expect you to become a better physician.

Attendings and Residents on the service:

Division Director: Karl Smith, MD
Gynecology Oncologist and Ob-Gyn Department Chairman: Guy Benrub, MD
Gyn-Onc Chief Resident: PGY4
Gyn-Onc 2nd Year Resident: PGY2

Key places at Shands Jacksonville:

- 3 South - Nursing Unit where most Gyn-Onc patients will be located
- ACC 3rd Floor – Clinic location
  - Gyn-Onc clinic meetings are on Thursday 8:30 a.m. until finished (usually about 12:30 p.m.)
  - See patients with a 2nd, 3rd or 4th year resident and present to attending
- Operating Rooms
  - Main OR – Main hospital building, 2nd Floor; Tuesday & Friday are Main OR days for Oncology
  - Outpatient Surgery Center (OSC) – LRC Building (Faculty Clinic, 1st Floor)

Learning Objectives:
Remember that all electronics were preceded by paper notes!!!
You are still learning. These are the important aspects of these evaluations and documentation.

Pre-op Note
If previous H&P more than 30 days old, need to do full H&P

S: major complaint inciting need for surgery
O: vitals
  Brief exam including general, heart, lungs, abd (with scars), ext
  Hgb, and any other labs or imaging related to perioperative morbidity
A/P: 31yo G3P3 with symptomatic pelvic organ prolapse for TVH with A & P repair.
  Risks, benefits, alternatives discussed. Consents signed.
  Plan for ovaries.

Op Note
Pre-Op Dx:
Post-Op Dx:
Procedure:
Attending:
Residents:
Anesthesia:
IVF:
UOP:
EBL:
Findings:
Specimen:
Complications:
Drains:
Disposition:

Post-Op Note
O: vitals
  Brief physical including general, heart, lungs, abd (bowel sounds, tenderness), incision (undo dressing
POD#1 and leave it undone until resident has seen it), ext (focus on signs of DVT, document SCDs)
  Urine output and post op hgb
A/P: 31yo G3P2 POD#1 s/p TAH/BSO LOA for fibroids
  1. post op -> doing well, d/c foley, ambulate, incentive spirometry, d/c PCA, advance diet
  2. htn -> will restart po meds
  3. anemia -> asx, will transfuse if necessary
Common Gynecologic Cancers –

☐ Cervical
  - Be able to recognize normal from abnormal cervix
  - Understand importance of HPV
  - Evaluation of abnormal Pap smears
  - Diagnosis and treatment of cervical dysplasia (cervical intraepithelial neoplasia)
  - Diagnosis, staging and treatment of invasive cervical cancer

☐ Endometrial
  - Who is at risk?
  - Evaluation of postmenopausal uterine bleeding
  - Management of endometrial hyperplasia
  - Diagnosis, staging and treatment of endometrial cancer

☐ Ovarian
  - Know basic types (epithelial, stromal and germ cell)
  - Who is at risk?
  - Understand evaluation process for pelvic masses
  - Diagnosis, staging and treatment of epithelial ovarian cancer

☐ Vulvar
  - Be able to recognize normal from abnormal appearing vulva
  - Recognize the vulvar inflammation from neoplasia
  - Recognize need for vulvar biopsy
  - Diagnosis and treatment of vulvar dysplasia
  - Diagnosis, staging and treatment of vulvar squamous cancer

Less Common Gynecologic Cancers –

☐ Vaginal

☐ Fallopian tube

☐ Trophoblastic Disease
  - Gestational
  - Non-Gestational

Other Cancers of Special interest to Gyn-Onc –

☐ Breast

☐ Colon
Treatment modalities –

- Surgery
- Radiation therapy
  - External beam (teletherapy)
  - Intracavitary (brachytherapy)
- Chemotherapy
  - Cytotoxic
  - Hormone therapy
  - Immunotherapy

Special Issues –

- Learn pelvic anatomy
- Symptom management
  - Pain
  - Nausea and vomiting
  - Chronic fatigue
  - Clinical depression
  - Diminished activity
- Associated medical problems
  - COPD
  - Heart disease
  - Hypertension
  - Diabetes Mellitus
  - Obesity
  - HIV
  - Others
- Social issues
  - Lack of funding
  - Lack of housing
  - Lack of transportation
  - Non-Compliance
1. **AccessMedicine by McGraw-Hill** –  
   This website has dozens of McGraw-Hill’s textbooks available online for free through the University of Florida Health Sciences Library website. The second link above is to the Off-Campus Proxy access, which can be utilized through the Gatorlink username and password (what you sign into UF Webmail with). Once on the Health Sciences Library website, the “Databases” list can be accessed to view the numerous databases available through UF. This is where access to PubMed, Clinical Pharmacology, UpToDate (which is not On Campus Only), and MD Consult can be found. In the scroll bar on the bottom half of the screen, click on AccessMedicine, which is the fourth database listed. This takes you to the AccessMedicine homepage. There are multiple tabs at the top of the page that allow access to textbooks from many disciplines, pathology images, procedure videos, case files, explanations of different diagnostic tests, and even Board Review material.

2. **New England Journal of Medicine, Procedure Videos** –  
   The NEJM has approximately 20 excellent basic procedure videos available that are central to medical care. The videos can be accessed by scrolling down to the “NEJM Audio and Video” box on the right hand side of the screen. Clicking on “More Procedure Videos” will enable access to the downloadable videos. The NEJM website has many other excellent resources available for free.

3. **American College of Surgeons, Division of Education** –  
   This is an excellent site for medical students and first year residents to learn basic surgical skills such as knot tying and use of basic surgical instruments. It has nice videos that are divided into three different phases depending on your skill and knowledge level. It requires a free registration. On the homepage, click on “Create new account” on the right half of the screen. Once registered, click on the phase you wish to review, and then proceed through the videos listed.

4. **National Comprehensive Cancer Network** –  
   [http://www.NCCN.org/](http://www.NCCN.org/)  
   This is an excellent online resource for clinical practice guidelines for many different types of cancer. It presents information on cancers in an easy to follow format that includes clinical presentation, treatment options (surgical and medical), recurrence probabilities, staging information, and discussions. It requires a free registration. On the NCCN homepage, the Clinical Practice Guidelines can be accessed by clicking on “NCCN Clinical Practice Guidelines in Oncology” under the “Clinical Recommendations” column on the bottom half of the page. The documents can be downloaded and/or printed from the website.

5. **Atlas of Pelvic Surgery** –  
   This is Cliff Wheelis’s gynecologic surgery book online. It has excellent diagrams and step-by-step approaches to numerous surgeries. All students on their Gynecology or Gynecology-Onc rotation should review these procedures prior to seeing them in the OR.

6. **ASCCP Colposcopy Course** –  
   [ASCCP Colposcopy Course.doc](ASCCP_Colposcopy_Course.doc)  
   This is a course prepared by the American Society for Colposcopy and Cervical Pathology that provides a quick guide to cervical anatomy, histology, and pathology. It also provides a guide to colposcopy, which should be reviewed before seeing patients in the Colposcopy Clinic.

7. **Understanding Risks of Ovarian Cancer Pamphlet** –  
   This pamphlet is an excellent guide to identifying the risk of hereditary gynecologic cancers. It is provided by the Gynecologic Cancer Foundation.
“Smith Notes” for Gyn Oncology

**Ovarian Cancer**

Types: Epithelial (most common), Stromal and Germ Cell

Diagnosis of epithelial cancer (serous, endometrioid, mucinous, undifferentiated; fallopian tube and primary peritoneal cancer)

1. Positive symptoms and exam: prolonged bloating, urinary frequency, indigestion, early satiety, abdominal swelling, constipation, pelvic mass, ascites.
2. Imaging: pelvic mass, ascites, omental thickening.

Treatment:

1. Laparotomy, TAH-BSO, omentectomy, lymph node excision, peritoneal biopsies, tumor debulking including bowel resection and colostomy if indicated. (Remember bowel prep)
2. Consider USO and staging for younger patients who wish to preserve fertility.
3. Post-op treatment
   a. IV chemotherapy (taxane and platin agent, e.g. paclitaxel/carboplatin)
   b. IV/IP chemotherapy (paclitaxel IV, cisplatin IP/paclitaxel IP)**
   c. No definite role for long term chemotherapy or 2nd look laparotomy

   **OR**

4. Neoadjuvant chemotherapy (paclitaxel/platin agent) 3-4 cycles at 3 week intervals.

Follow-up: exams every 3-4 months for 2 years then q6 months until 5 years from diagnosis, then yearly. (see Table 3 Surveillance for Gynecologic Cancer, Sabani, Am J Obstet Gynecol, 2011)

In patients with complete response to initial surgery and chemotherapy recurrence occurs in 50% within 2-3 years of initial diagnosis.
Endometrial Cancer

Diagnosis:

1. Postmenopausal bleeding
2. Abnormal image (thickened endometrial stripe, irregular endometrial cavity or fluid in cavity on CT or MRI
3. Positive endometrial biopsy
4. Thickened endometrium with irregular contour by hysteroscopy
5. Positive endometrial curettages on D&C
6. Consider abdominal and pelvic CT with oral and IV contrast

Treatment: Surgery:

1. TAH-BSO, pelvic and para-aortic lymph node dissection (open through vertical incision, laparoscopic or robotic, peritoneal biopsies and omentectomy for serous or clear cell cancers)
2. Radical hysterectomy, BSO, LND for Stage II (cervical involvement)
   OR
3. Pre-op RT followed in 6 weeks by TAH-BSO

Post Op treatment: (follow NCCN guidelines)

1. Radiation therapy if positive lymph nodes or previously unrecognized spread to cervix.
2. Chemotherapy with or without RT if peritoneal, omental or intestinal spread of disease.
3. Chemotherapy for special tumor types (serous, clear cell, or malignant mixed mesodermal tumor)
4. Special consideration for endometrial stomal leiomyosarcomas

Follow-up:

Exam q6 month for 2 years then q6 months until 5 years after diagnosis (see Table 2, Surveillance for Gynecologic Cancer, Sabani, Am J Obstet Gynecol, 2011)

Most common site of recurrence is vagina followed by lung, abdomen, and retroperitoneal lymph nodes. Get CT only if symptoms or physical findings.
Cervical Cancer

Diagnosis:

1. Biopsy if visible cervical mass
2. Cervical cone if suspicious Pap or cervical colposcopy
3. Pelvic exam under anesthesia (EUA) often includes cytoscopy and proctoscopy. Radiation oncologist present.
4. PET/CT base of skull to mid thigh to look for metastasis

Treatment:

1. Micro-invasive cancer up to 3 mm – simple hysterectomy, diagnosis cannot be made by simple biopsy, must be made by cone.
2. Cervical mass confined to cervix ≤ 4 cm – radical hysterectomy with pelvic and para-aortic lymph node dissection. Ovaries may be preserved.
   OR
3. Cervical mass ≥ 4 cm or spread of disease outside cervix – radiation therapy.
   a. External pelvic RT with weekly cisplatin chemotherapy (40 mg/M²)
   b. Intra-cavitary RT × 2 (T&O or Syed)

4. Ureteral stent or nephrostomy if ureteral obstruction

Follow-up:

1. Use vaginal dilator weekly if patient received RT
2. Exam q6 month × 2 years then q6 months until 5 years after diagnosis.
   (see Table 5 Surveillance for Gynecologic Cancer, Sabani, Am J Obstet Gynecol, 2011)
3. Recurrence occurs within 2-3 years in most cases where there is recurrence.
Vulvar Cancer

Diagnosis:

1. Usually made visual inspection and biopsy.
2. Biopsy may be performed in office setting or OR
3. Assessment requires careful palpation of groin lymph nodes, size of tumor, and location with regard to urethra, vagina and anus.
4. Imaging is individualized; consider chest, abdomen and pelvic CT if groin nodes are enlarged or fixed. PET/CT from base of skull to mid-thigh may be an option. Chest x-ray if CT or PET are not performed.

Treatment:

1. Surgery is the primary treatment for vulvar cancer.
   a. Excise lesion with 5 mm margin if invasion not suspected
   b. Radical partial vulvectomy with at least 1 cm margin in invasive cancer is suspected. Use two or three incision technique for vulva and groin incisions.
      1) Perform ipsilateral lymph node dissection if lesion does not cross the midline.
      2) Perform bilateral lymph node dissection if ipsilateral nodes are involved on frozen section or if lesion crosses midline.
   c. Postop pelvic RT if lymph nodes are involved.
2. Consider chemoradiation for lesions for invasive cancers involving urethra or anus.

Follow-up:

1. Physical exam including care pelvic exam to look for local recurrence q 6 months for 2 years, then yearly (see Table 5 in Surveillance for gynecologic Cancers by Sabani, Am J Obstet Gynecol, 2011).
2. Consider imaging studies such as CT only with onset of symptoms or a new physical finding that suggests recurrent cancer.
Vaginal Cancer

Diagnosis:

1. Usually presents as mass in vagina
2. Requires biopsy for diagnosis
3. PET/CT for metastatic evaluation
4. Consider EUA

Treatment:

1. Usually RT (FPRT with weekly cisplat and brachytherapy (IVRT)
2. Consider transvaginal excision of non-invasive cancer

Follow-up:

1. Exam q6 months with Pap x 2 years then yearly (see Table 5 in Surveillance for gynecologic Cancers by Sabani, Am J Obstet Gynecol, 2011).
2. CT of abdomen and pelvis with oral and IV contrast if symptom or sign of recurrence,
GTD

Diagnosis:

1. Molar pregnancy
   a. Abnormal sonogram
   b. Endometrial suction curettage
   c. Serial quantitative serum hCG levels
   d. Chest x-ray if hCG rises
2. After prior IUP (term, SAB, or ectopic)
   a. Serial quantitative serum hCG, consider hCG-H
   b. Chest, abdomen, and pelvic CT if rising hCG
3. Determine WHO score

Treatment:

1. Single agent methotrexate or actinomycin D for post molar and low risk disease
2. Multiple agents (EMA-CO) for recurrent or high risk disease
3. Give at least one treatment after negative hCG

Follow-up:

1. Oral contraceptive agent or Depo Provera for at least 6 months
2. Monthly serum hCG
3. Get early pelvic sonogram if pregnancy suspect after previous treatment for GTD
Gyn Oncology Staging

Endometrial Cancer (FIGO 2009)

Stage I: Tumor confined to the corpus uteri

IA*: no or less than ½ myometrial invasion
IB*: invasion equal to or more than half of the myometrium

Stage II#: Tumor invades the cervical stroma, but does not extend beyond the uterus.

Stage III: Local and/or regional spread of the tumor

IIIA: Tumor invades the serosa of the corpus uteri and/or adnexae
IIIB: Vaginal and/or parametrial involvement
IIIC: Metastases to pelvic and/or para-aortic lymph nodes

IIIC1: Positive pelvic lymph nodes
IIIC2: Positive para-aortic lymph nodes with or without Positive pelvic lymph nodes.

Stage IV: Tumor invades bladder and/or bowel mucosa, and/or distant metastases.

IVA: Tumor invasion of bladder and/or bowel mucosa
IVB: Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes.

* Any grade (G1, G2, G3); Serous and Clear cell are always grade 3
# Endocervical glandular involvement only should be considered as Stage I and no longer as Stage II.
Positive cytology should be reported separately without changing stage
Adverse risk factor to be consider in treatment (see NCCN guidelines):
  age >60 years
  positive lymphvascular space invasion
  Lower uterine segment (cervical/glandular) involvement.
Uterine Sarcoma* (FIGO 2009)

Stage I  Tumor limited to uterus
   Stage IA: Tumor 5 cm or less in greatest dimension
   Stage IB: Tumor greater than 5 cm

Stage II  Tumor extends beyond the uterus, but within the pelvis
   Stage IIA: Tumor invades adnexa
   Stage IIB: Tumor invades other pelvic tissues

Stage III  Tumor infiltrates abdominal tissues
   (not just protruding into abdominal cavity)
   Stage IIIA: One site
   Stage IIIB: More than one site
   Stage IIIC: Regional lymph node metastasis

Stage IV  Distant spread of cancer
   IVA: Tumor invades bladder or rectum
   IVB: Distant metastasis (lung, liver, brain, para-aortic LN, etc.)

Notes:  1. Carcinosarcoma should be staged as carcinomas of endometrium
        2. Simultaneous tumors of the uterine corpus and ovary/pelvis in
           association with ovarian/pelvic endometriosis should be classified as
           independent primary tumors.
        3. *Types of uterine sarcoma: leiomyosarcoma, undifferentiated
           sarcoma, and endometrial stromal sarcoma
**Invasive Cervical Cancer (FIGO 2009)**

**Stage I** cancer confined to cervix

Stage IA  invasion diagnosed by microscope only

Stage IA1 invasion not greater than 3.0 mm in depth or 7 mm in width

Stage IA2 invasion > 3 mm but < 5 mm and less than 7 mm in width

Stage IB invasion > 5 mm in depth or > 7 mm in width or clinically visible Lesion.

Stage IB1 lesion ≤ 4.0 cm

Stage IB2 lesion > 4.0 cm

**Stage II** Invasion beyond cervix but not to pelvic side wall or lower 1/3rd of vagina

Stage IIA1 Tumor extending to upper vagina without parametrial extension

Visible tumor ≤ 4 cm in greatest dimension

Stage IIA2 Tumor extending to upper vagina without parametrial extension

Visible tumor > 4 cm

Stage IIB Tumor extending to parametrium, any size

**Stage III** Tumor extends to pelvic sidewall and/or involves lower 1/3rd of vagina and/or causes hydrenephrosis or nonfunctioning kidney.

Stage IIIA  Tumor extends to lower 1/3rd of vagina but without extension to pelvic sidewall

Stage IIIB  Tumor extends to pelvic sidewall and/or causes hydrenephrosis or nonfunctioning kidney.

**Stage IV** Tumor extends beyond uterus to mucosa or bladder or rectum and/or true pelvis

(Bullus edema of bladder is not sufficient to qualify as Stage IV)
Ovarian Cancer and Primary Peritoneal Cancer (FIGO 2009)

Stage I Tumor limited to ovaries (one or both)
- Stage IA Tumor limited to one ovary; capsule intact, no tumor on ovarian Surface. No malignant cell in ascites or peritoneal washings.
- Stage IB Tumor limited to both ovaries; capsule intact, no tumor on ovarian Surface.
- Stage IC Tumor limited to one or both ovaries with any of the following:
  - Capsule ruptured, tumor on ovarian surface, malignant cell in ascites or peritoneal washings.

Stage II Tumor involves one or both ovaries with pelvic extension
- Stage IIA Tumor involves uterus and/or fallopian tube(s).
  - No malignant cell in ascites or peritoneal washings
- Stage IIB Tumor extension or implants on otho pelvic tissues
  - No malignant cell in ascites or peritoneal washings
- Stage IIC Tumor extension or implants involving uterus, fallopian tubes or other pelvic tissues with malignant cell in ascites or peritoneal washings

Stage III Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis.
- Stage IIIA Microscopic peritoneal metastasis beyond pelvic (no macroscopic tumor)
- Stage IIIB Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension.
- Stage IIIC Macroscopic peritoneal metastasis beyond pelvis greater than 2 cm or less in greatest dimension and/or regional lymph node metastasis.

Stage IV Distant metastasis (e.g. malignant pleural effusion, liver parenchymal mets, invasion of mucosa of bladder or rectum, but not peritoneal metastasis.)
**Vulvar Cancer** (FIGO 2009)

**Stage I** Tumor confined to the vulva or perineum

IA: Lesion ≤ 2 cm in size and confined to vulva or perineum; Stromal invasion is ≤ 1 mm*. No nodal metastasis

IB: Lesions > 2 cm in size or with stromal invasion ≥ 1 mm confined to vulva or perineum. No nodal metastasis

**Stage II** Tumor of any size with extension to adjacent perineal structures (lower 1/3 of urethra, lower 1/3 of vagina or anus) and no nodal metastasis.

**Stage III** Tumor of any size with or without extension to adjacent perineal structures (lower 1/3 of urethra, lower 1/3 of vagina or anus) with positive inguino-femoral lymph nodes.

IIIA
(i) with 1 lymph node metastasis (≥5 mm), or
(ii) 1-2 lymph node metastases (≤5 mm)

IIIB
(i) with 2 or more lymph node metastases (≥5 mm)
(ii) 3 or more lymph node metastases (≤5 mm)

IIIC with positive node with extracapsular spread

**Stage IV** Tumor invades other regional sites (upper 2/3 urethra, upper 2/3 vagina or distant structures.

IVA: Tumor invades any of the following:
(i) upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, or fixed to pelvic bone, or
(ii) fixed or ulcerated inguino-femoral lymph nodes.

IVB: any distant metastasis including pelvic lymph nodes.
**Vaginal Cancer**  
*(clinical staging)*

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Carcinoma <em>in situ</em> (VaLN 3) – non invasive</td>
</tr>
<tr>
<td>I.</td>
<td>Invasive cancer limited to vaginal wall</td>
</tr>
<tr>
<td>II.</td>
<td>Involvement of subvaginal tissue but without extension to pelvic sidewall</td>
</tr>
<tr>
<td>III.</td>
<td>Extension to pelvic sidewall</td>
</tr>
<tr>
<td>IVA.</td>
<td>Extension to beyond true pelvis or involvement of bladder or rectal mucosa. Bullous edemadoes not permit a case to be assigned to stage IV</td>
</tr>
<tr>
<td>IVB.</td>
<td>Spread to adjacent organs and/or direct extension beyond the true Pelvis; Spread to distant organs</td>
</tr>
</tbody>
</table>

*(Hoskins, Principles and Practice of Gynecologic Oncology, 4th edition, 2005)*
**Gestational Trophoblastic Disease**  (FIGO ANATOMIC STAGING)

**Stage I**  Disease confined to uterus  
**Stage II**  GTN extends outside uterus, but is limited to the genital structures  
**Stage III**  GTN extends to the lungs, with or without known genital tract involvement  
**Stage IV**  All other metastatic sites

(GTN = Gestational trophoblastic neoplasia)

### WHO/FIGO Staging (2000)

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>&lt;39</td>
<td>&gt;39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antecedent preg</td>
<td>H. Mole</td>
<td>abortion</td>
<td>Term preg</td>
<td></td>
</tr>
<tr>
<td>Time interval (m)</td>
<td>&lt;4</td>
<td>4 - 6</td>
<td>7 - 12</td>
<td>&gt;12</td>
</tr>
<tr>
<td>HCG (serum, mIU/ml)</td>
<td>&lt;10^3</td>
<td>10^3 - 10^4</td>
<td>10^4 - 10^5</td>
<td>&gt;10^5</td>
</tr>
<tr>
<td>No. Mets</td>
<td>0</td>
<td>1 - 4</td>
<td>4 - 8</td>
<td>&gt;8</td>
</tr>
<tr>
<td>Site of Mets</td>
<td>Lungs</td>
<td>spleen</td>
<td>Gl tract</td>
<td>Brain</td>
</tr>
<tr>
<td>Largest tumor (cm)</td>
<td>3 - 5</td>
<td>&gt;5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior chemotherapy</td>
<td>single drug</td>
<td>2 or more drugs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

To determine total score, add individual scores.  
Rescore after each change in chemotherapy.  
4 = low risk; 5-7 = medium risk; 8 or > = high risk
<table>
<thead>
<tr>
<th>POPULATION</th>
<th>PAGE NUMBER</th>
<th>RECOMMENDED SCREENING METHOD&lt;sup&gt;a&lt;/sup&gt;</th>
<th>MANAGEMENT OF SCREEN RESULTS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aged &lt; 21 y</td>
<td>153</td>
<td>No screening</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aged 21-29 y</td>
<td>154-155</td>
<td>Cytology alone every 3 y</td>
<td>HPV-positive ASC-US&lt;sup&gt;b&lt;/sup&gt; or cytology of LSIL or more severe: Refer to ASCCP guidelines&lt;sup&gt;2&lt;/sup&gt;</td>
<td>HPV testing should not be used for screening or management of ASC-US in this age group</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cytology negative or HPV-negative ASC-US&lt;sup&gt;b&lt;/sup&gt;: Rescreen with cytology in 3 y</td>
<td></td>
</tr>
<tr>
<td>Aged 30-65 y</td>
<td>155-162</td>
<td>HPV and cytology &quot;cotesting&quot; every 5 y (preferred)</td>
<td>HPV-positive ASC-US or cytology of LSIL or more severe: Refer to ASCCP guidelines&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Screening by HPV testing alone is not recommended for most clinical settings</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HPV positive, cytology negative: Option 1: 12-mo follow-up with cotesting Option 2: Test for HPV16 or HPV16/18 genotypes • If HPV16 or HPV16/18 positive: refer to colposcopy • If HPV16 or HPV16/18 negative: 12-mo follow-up with cotesting</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cotest negative or HPV-negative ASC-US: Rescreen with cotesting in 5 y</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cytology alone every 3 y (acceptable)</td>
<td>HPV-positive ASC-US&lt;sup&gt;b&lt;/sup&gt; or cytology of LSIL or more severe: Refer to ASCCP guidelines&lt;sup&gt;2&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cytology negative or HPV-negative ASC-US&lt;sup&gt;b&lt;/sup&gt;: Rescreen with cytology in 3 y</td>
<td></td>
</tr>
<tr>
<td>Aged &gt; 65 y</td>
<td>162-163</td>
<td>No screening following adequate negative prior screening</td>
<td></td>
<td>Women with a history of CIN2 or a more severe diagnosis should continue routine screening for at least 20 y</td>
</tr>
<tr>
<td>After hysterectomy</td>
<td>163-164</td>
<td>No screening</td>
<td></td>
<td>Applies to women without a cervix and without a history of CIN2 or a more severe diagnosis in the past 20 y or cervical cancer ever</td>
</tr>
</tbody>
</table>
Criteria for Genetic Risk Assessment

Patients with greater than an approximate 20-25% chance of having an inherited predisposition to breast cancer and ovarian cancer and for whom genetic risk assessment is recommended:

- Women with a personal history of both breast cancer and ovarian cancer*
- Women with ovarian cancer* and a close relative† with ovarian cancer or premenopausal breast cancer or both
- Women with ovarian cancer* who are of Ashkenazi Jewish ancestry
- Women with breast cancer at age 50 years or younger and a close relative† with ovarian cancer* or male breast cancer at any age
- Women of Ashkenazi Jewish ancestry in whom breast cancer was diagnosed at age 40 years or younger
- Women with a close relative† with a known BRCA1 or BRCA2 mutation

Patients with greater than an approximate 5-10% chance of having an inherited predisposition to breast cancer and ovarian cancer and for whom genetic risk assessment may be helpful:

- Women with breast cancer at age 40 years or younger
- Women with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer of high grade, serous histology at any age
- Women with bilateral breast cancer (particularly if the first case of breast cancer was diagnosed at age 50 years or younger
- Women with breast cancer at age 50 years or younger and a close relative† with breast cancer at age 50 years or younger
- Women of Ashkenazi Jewish ancestry with breast cancer at age 50 years or younger
- Women with breast cancer at any age and two or more close relatives† with breast cancer at any age (particularly if at least one case of breast cancer was diagnosed at age 50 years or younger)
- Unaffected women with a close relative† that meets one of the previous criteria

*Cancer of the peritoneum and fallopian tubes should be considered a part of the spectrum of the hereditary breast and ovarian cancer syndrome.

†Close relative is defined as a first-degree relative (mother, sister, daughter) or second-degree relative (grandmother, granddaughter, aunt, niece).
Checklist for surveillance of gynecologic malignancies

Patient name_____________________________________
Visit date_______________________________________
Disease site and stage__________________________________________
Date of diagnosis/surgery_______________________________________
Date treatment completed_______________________________________

Symptoms review and treatment side-effects
- Pain (abdominal or pelvic, hip or back)
- Abdominal bloating
- Vaginal bleeding (also rectum, bladder)
- Weight loss
- Nausea and/or vomiting
- Cough or shortness of breath
- Lethargy/fatigue
- Swelling of abdomen or leg(s)
- Depression
- Sexual dysfunction
- Neuropathy
- Fatigue

Physical examination
- General physical examination targeted to symptoms
- Lymph node assessment (axillary, supraclavicular, and inguinal)
- Pelvic examination (evaluation of lower genital tract, speculum, bimanual, rectovaginal examination)

Laboratory
- Tumor markers_______________________________________

Disease status
- No evidence of disease
- Suspect recurrence
  - Radiographic imaging___________________________________
  - Biopsy___________________________________________
  - Refer to gynecologic oncologist

Routine health maintenance

Breast cancer screening
- Yearly clinical breast examination______________________
- Mammogram________________________________________
  Every 1-2 years starting with ages 40-49 years, then yearly

Colon cancer screening
- Colonoscopy or flexible sigmoidoscopy____________________
  Every 5-10 years beginning at age 50 years

Genetic screening
- Not indicated
- Recommended/completed______________________________
  Consider if patient is diagnosed at a young age, strong family history, multiple primaries (see specific surveillance guidelines)

Menopausal assessment

Osteoporosis prevention
- Calcium (1200-1500 mg) and vitamin D (800 IU)
- Bone mineral density testing
  Begin at age 65 years (sooner if high risk factors)

Smoking cessation

Weight maintenance (exercise, diet)

ONCOLOGY

Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations

Ritu Salani, MD, MBA; Floor J. Backes, MD; Michael Fung Kee Fung, MB, BS; Christine H. Holschneider, MD; Lynn P. Parker, MD; Robert E. Bristow, MD, MBA; Barbara A. Goff, MD

Although gynecologic cancers account for only 10% of all new cancer cases in women, these cancers account for 20% of all female cancer survivors. Improvements in cancer care have resulted in almost 10 million cancer survivors, and this number is expected to grow. Therefore, determining the most cost-effective clinical surveillance for detection of recurrence is critical. Unfortunately, there has been a paucity of research in what are the most cost-effective strategies for surveillance once patients have achieved a complete response. Currently, most recommendations are based on retrospective studies and expert opinion. Taking a thorough history, performing a thorough examination, and educating cancer survivors about concerning symptoms is the most effective method for the detection of most gynecologic cancer recurrences. There is very little evidence that routine cytologic procedures or imaging improves the ability to detect gynecologic cancer recurrence at a stage that will impact cure or response rates to salvage therapy. This article will review the most recent data on surveillance for gynecologic cancer recurrence in women who have had a complete response to primary cancer therapy.

Key words: cervical cancer, cytology, endometrial cancer, gynecologic cancer, imaging, ovarian cancer, surveillance

In 2010, gynecologic malignancies were expected to afflict approximately 80,000 women within the United States. Advances within the field of gynecologic oncology have resulted in long-term survivals and a high rate of survivors. Because long-term survival is becoming more common in this patient population, insights into cancer surveillance and detection of recurrence and addressing side-effects from treatment are of utmost importance.

Currently, posttreatment guidelines call for frequent visits immediately after treatment, followed by increasing intervals over time. Typically, after the first 2-3 years, patients are transitioned back to their primary care providers. However, primary care physicians may not be comfortable with guidelines or surveillance for each specific cancer type. This is in part due to a lack of training and in part to unclear expectations for the primary care provider by the oncologist.

As survivorship continues to grow, coordination of care between gynecologic oncologists, primary care providers, other healthcare providers (such as radiation oncologists), and patients ideally will allow for compliance with cancer follow-up care and routine health maintenance. The provision of a clear understanding of recommendations and responsibilities of appropriate surveillance will reduce unnecessary tests and ultimately result in cost savings.

The role of surveillance is to provide clinical and cost-effective practices that detect recurrence and impact survival outcomes. Acceptance of surveillance should be considered if there is utility of treatment for recurrence and decreased morbidity from both monitoring for disease recurrence and treatment. One should also consider the costs and the use of resources for conducting these tests. Last, patients should be counseled on the benefits and pitfalls of disease monitoring, which should include the psychologic impact of surveillance programs. Unfortunately, most studies across all cancer sites are based predominantly on retrospective studies and provide limited insight into the true benefit of recommended guidelines for posttreatment surveillance. There is a need for prospective studies to establish the most cost-effective methods for the detection of recurrent disease. In addition, surveillance tests should be directed at detecting recurrences that are amenable to curative or significant palliative treatment. Therefore, the primary objective of this review is to provide the most recent data on surveillance for cancer recurrence in women who have had a complete response to primary cancer therapy for gynecologic malignancies. Additionally, we have included routine health screen-
ing guidelines to allow for enhanced communication between oncologists and primary care providers.

Endometrial cancer
Endometrial cancer is the most common gynecologic cancer and the fourth most common cancer in women. Yearly, there are approximately 44,000 new endometrial cancer diagnoses and 8000 deaths in the United States. Commonly, patients experience symptoms such as abnormal or postmenopausal bleeding, which warrant further investigation with ultrasound scanning and/or endometrial sampling. The combination of symptoms and diagnostic testing results in 83% of patients being diagnosed in the early stages of the disease. As a result of localized disease, 5-year survival rates exceed 95% for stage I and approach 83% overall. However, recurrence rates for patients with early-stage disease range from 2-15% and reach as high as 50% in advanced stages or in patients with aggressive histologic condition. Many local recurrences from endometrial cancer are curable; therefore, the determination of the ideal time interval and diagnostic tools for surveillance of recurrent endometrial cancer that can impact survival outcomes is critical.

Typically, surveillance guidelines are more intensive the first few years after diagnosis because many studies have shown that most (70-100%) recurrences occur within 3 years after primary treatment. Current guidelines of the National Comprehensive Cancer Network (NCCN) and the American Congress of Obstetricians and Gynecologists recommend physical examination every 3-6 months for 2 years, then every 6 months or annually. Further evaluation with vaginal cytologic evidence is recommended every 6 months for 2 years and annually thereafter. To date, there are no prospective studies that have evaluated the role of surveillance in endometrial cancer follow-up evaluation. Based on recommended guidelines and institutional practices, retrospective research and literature reviews comprise the best evidence that is available.

The most consistently used method for surveillance is the physical examination. This alone accounts for a high rate of detection that ranges from 35-68% of cases. Even more striking is that the combination of physical examination and symptoms has resulted in rates of detection that exceed 80%. In a recent literature review, Sartori et al report that only physical examination has shown utility in the detection of endometrial cancer recurrence. Therefore, physical examination, which includes a thorough speculum, pelvic, and rectovaginal examination, should be conducted during each follow-up assessment.

The role of surveillance is based on the concept that detection of recurrences in the asymptomatic stage results in better therapeutic options and outcomes. Interestingly, even in spite of intensive surveillance, many recurrences are detected based on the presence of symptoms, which occurs in 41-83% of patients. A common symptom, vaginal bleeding, is indicative of a local recurrence that is often curable if it is an isolated site of disease. However, other common symptoms include abdominal and/or pelvic pain, lethargy, and weight loss. Even in the face of monitoring for recurrence, patients who experience a distant recurrence are symptomatic in 70% of cases, such as coughing or headaches. Therefore, patient education about the signs and symptoms is a critical component of posttreatment care and may lead to the detection of recurrent disease.

Survival outcomes have been evaluated on the basis of the presence or absence of symptoms at the time of recurrence. In a report by Sartori et al, 52% of patients were diagnosed with recurrence after they had symptoms; these patients had a median postrecurrence survival of 7 months. This was significantly less than the 20-month survival that patients experienced if they were diagnosed with recurrence in an asymptomatic state that was based on examination or imaging. Several other series have evaluated the role of routine surveillance for the follow-up evaluation of patients with stage I endometrial cancer and reported no difference in survival based on the presence or absence of symptoms. Of note, even patients who had symptoms were undergoing the recommended follow-up evaluations, which provided an argument against the use of routine surveillance. Although all of these studies were retrospective, they reiterate the importance of prospective trials to determine the true role and regimen for surveillance.

Because most recurrences occur at the vaginal cuff, the use of cytologic evaluation has been advocated. However, many gynecologic oncologists challenge this recommendation. Rates of recurrence detection on vaginal cytologic evidence range from 0-6.8%, even in asymptomatic patients. Although Berchuck et al and Owen and Duncan report that cytologic evaluation detected 25% of all recurrences and that cytologic evaluation alone detected only 3 of the 44 (7%) recurrences. Furthermore, in addition to a low yield of detection, Agboola et al reported that the use of vaginal cytologic evaluation at each visit resulted in a cost of $27,000 per case detected. Because most recurrences at the vaginal cuff can be found on examination, vaginal cytologic evaluation adds only significant healthcare costs without added benefit.

Similarly to ovarian cancer, the use of cancer antigen 125 (CA125) level has been investigated as a marker for recurrence. In asymptomatic patients with endometrial cancer, the use of CA125 levels accounted for 15% of detections. Rose et al reported that CA125 levels were elevated in more than one-half of the patients with advanced stage and/or high-grade histologic evidence and that of these patients most had an elevated pretreatment level. However, one must be aware of elevated CA125 levels because of other conditions or even previous radiotherapy. In addition, the role of CA125 levels for the detection of recurrence was negligible in patients with low-risk disease. At present, the use of CA125 levels should not be used routinely in patients with endometrial cancer but may be appropriate in select patients with advanced disease, serious histologic condition, or a CA125 level that is elevated before treatment.

The use of radiographic imaging has been suggested for the detection of re-
TABLE 1
Sensitivity/detection rate of the methods that were used to detect recurrence in patients at routine visits after treatment

<table>
<thead>
<tr>
<th>Method of detection</th>
<th>Type of cancer, %</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Endometrial</td>
<td>Ovarian</td>
<td>Cervical</td>
<td></td>
</tr>
<tr>
<td>Symptoms</td>
<td>41-83</td>
<td>—</td>
<td>46-95</td>
<td></td>
</tr>
<tr>
<td>Physical examination</td>
<td>35-68</td>
<td>15-78</td>
<td>29-75</td>
<td></td>
</tr>
<tr>
<td>Cytologic evidence</td>
<td>0-7</td>
<td>—</td>
<td>0-17</td>
<td></td>
</tr>
<tr>
<td>Chest radiograph</td>
<td>0-20</td>
<td>—</td>
<td>20-47</td>
<td></td>
</tr>
<tr>
<td>Cancer antigen 125 level</td>
<td>15</td>
<td>62-74</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Computed tomography scan</td>
<td>0-20</td>
<td>40-93</td>
<td>0-45</td>
<td></td>
</tr>
<tr>
<td>Positron emission test–computed tomography scan</td>
<td>100*</td>
<td>45-100</td>
<td>86</td>
<td></td>
</tr>
</tbody>
</table>

* Limited data.


Current disease. Because of low costs, chest radiographs have been advocated for the detection of asymptomatic recurrences, often on a semiannual or annual basis. The rate of detection for asymptomatic chest recurrences that are found on chest radiographs ranges from 0–20%. In another series, chest radiographs detected 7 asymptomatic pulmonary recurrences and accounted for 0.34% of all chest radiographs that were performed for surveillance, which indicates low utility for this tool. Although reports of isolated pulmonary recurrences, albeit rare, may be amenable to therapies that allow for long-term survival outcomes, the routine use of chest radiographs is not recommended. In further evaluation of radiographic imaging for endometrial cancer surveillance, Fung Kee Fung et al conducted a review of the literature and found that only 5-21% of asymptomatic recurrences were found by computed tomography (CT) scans. Other studies have agreed that the role of CT scanning for asymptomatic patients is not warranted, because survival of patients with disease that is detected on CT scan, compared with clinical examination, did not differ significantly. To increase the detection of local recurrence, the use of pelvic ultrasound scans has also been reported. Although detection rates for local recurrence range from 4–31%, many of these recurrences were also detected on other diagnostic methods, which included physical examination. Therefore, the use of routine pelvic ultrasound and CT scanning is not advocated; however, these modalities may play a role in the evaluation of patients with symptoms, because the rates of detection approach 50% of cases. More recently, attention has been focused on positron emission test (PET) or CT scans for endometrial cancer recurrence. Park et al reported 100% sensitivity and 83% specificity when PET-CT scanning was used for suspected recurrence and 100% diagnostic accuracy in 64 asymptomatic patients. However, its use for routine screening has not been well studied, and larger prospective studies will determine whether PET/CT will have a role in endometrial cancer surveillance. In addition, the high cost of PET/CT may limit its use in routine surveillance (Table 1).

In conclusion, most patients with endometrial cancer will be a low risk for recurrence, and more than one-half of all recurrences will be detected through symptoms alone. With the exception of local disease, recurrent endometrial cancer is associated with a poor prognosis, regardless of the time of detection. On the basis of the data, we recommend a surveillance regimen to include a thorough history and physical examination, which would include a speculum and pelvic examination, at scheduled intervals with further testing indicated to evaluate symptoms and abnormalities that are detected on examination. This approach may save valuable healthcare dollars. Cytologic evaluation and chest radiographs in asymptomatic women are not clearly beneficial. If patients do have a suspected recurrence, generally a CT scan of chest, abdomen, and pelvis or PET/CT scans may be performed to assess the extent of the disease (Table 2).

Ovarian cancer
Ovarian cancer affects almost 22,000 women each year in the United States and results in >13,000 deaths yearly. Although responsible for <30% of all gynecologic malignancies, ovarian cancer accounts for >50% of deaths. These results stem from a lack of accurate screening tools and symptoms that are vague and often not specific, which result in approximately 75% of patients being diagnosed with advanced disease. Since the 1970s, the median overall survival of patients with advanced ovarian cancer has increased from 20 months up to 65 months because of advances in surgery and chemotherapy.

Despite the achievement of a complete clinical response, recurrence rates remain high, occurring in 25% of patients with early-stage disease and >80% of patients with advanced disease. Although patients with recurrent ovarian cancer rarely are cured, patients can have significant responses to salvage treatments.

To detect recurrences, the NCCN guidelines for epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer recommend follow-up visits every 2-4 months for the first 2 years, followed by 6-month intervals for the next 3 years. At each visit, physical examination and identification of the CA125 level or corresponding tumor marker are recommended. Additionally, these guidelines advocate the use of radiographic imaging and laboratory testing, as clinically indicated. However, the impact of surveillance and guidelines are based predominantly on retrospective studies and expert opinions.

Because 26-50% of recurrences occur within the pelvis, a thorough physical examination is an important part of a patient’s follow-up care and should include a bimanual pelvic and rectovaginal ex-
TABLE 2
Endometrial cancer surveillance recommendations

<table>
<thead>
<tr>
<th>Variable</th>
<th>Months</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-12</td>
<td>12-24</td>
</tr>
<tr>
<td>Review of symptoms and physical examination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low risk (stage IA grade 1 or 2)</td>
<td>Every 6 mo</td>
<td>Yearly</td>
</tr>
<tr>
<td>Intermediate risk (stage IB-II)</td>
<td>Every 3 mo</td>
<td>Every 6 mo</td>
</tr>
<tr>
<td>High risk (stage IIA, serous or clear cell)</td>
<td>Every 3 mo</td>
<td>Every 3 mo</td>
</tr>
<tr>
<td>Papanicolaou test/cytologic evidence</td>
<td>Not indicated</td>
<td>Not indicated</td>
</tr>
<tr>
<td>Cancer antigen 125</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
</tr>
<tr>
<td>Radiographic imaging (chest x-ray, positron emission tomography/computed tomography, magnetic resonance imaging)</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
</tr>
<tr>
<td>Recurrence suspected</td>
<td>Computed tomography and/or positron emission tomography scan ± cancer antigen 125</td>
<td>Computed tomography and/or positron emission tomography scan ± cancer antigen 125</td>
</tr>
</tbody>
</table>

* May be followed by a generalist or gynecologic oncologist. **Consider alternating visits with a generalist and gynecologic oncologist.


amination. However, the rates of detection by physical examination vary significantly from 15-78%. Although physical examination is one of the most commonly used tools and is associated with low cost, the reproducibility is low and may not detect other common sites of disease recurrence, such as the retroperitoneal lymph nodes, upper abdominal organs, or lungs. Thus, in a patient with symptoms or tests that are concerning for recurrence, physical examination alone may not be sufficient.

Historically, second-look surgeries have been used to assess disease response to primary treatment. Despite negative findings, recurrence rates that range from 35-50% have been reported, and no benefit in overall survival was noted. Thus, this procedure fell out of favor and is used rarely today.

Since its discovery in 1981, the use of CA125 level for tumor recurrence has been evaluated extensively. Approximately 80% of epithelial tumors will have an elevated CA125 level at the time of diagnosis. Studies have shown that CA125 level correlates with disease status in most cases and is often elevated 2-5 months before clinical detection of relapse. Generally, the sensitivity and specificity for CA125 level and disease recurrence ranges from 62-94% and 91-100%, respectively. In 255 patients who had completed primary therapy, a CA125 level twice the upper limits of normal was consistent with disease progression in almost all patients who were evaluated. Santillan et al reported that CA125 levels with a persistently low level of increase, even within normal values of the test, were often consistent with tumor recurrence. However, other reports found that the detection of recurrent disease by CA125 level alone yielded no prognostic benefit and advocate the use of CA125 level for surveillance only after a discussion that would explain the interpretation of the test.

Furthermore, in a recently completed prospective randomized trial, the European Organization for Research and Treatment of Cancer assessed the outcome of 527 patients who were treated for recurrent ovarian cancer based on CA125 level alone vs clinically evident recurrence. The overall survival outcome did not differ for either group, and the investigators concluded that routine measurement of CA125 level is not warranted for disease surveillance.

To improve early detection of recurrent disease, the role of radiographic imaging modalities has been investigated. In a retrospective analysis, surveillance with CT scans every 6 months for the first 2 years, followed by yearly intervals, demonstrated the ability to detect asymptomatic disease. The authors reported a higher rate of optimal secondary cytoreductive surgery and an improved overall survival in the group with recurrence detected asymptptomatically, compared with the symptomatic recurrence. Other studies that have evaluated methods of surveillance for ovarian cancer have reported the sensitivity of CT scans to be 40-93% and the specificity to be 50-98% for recurrent disease. On the contrary, in a study of 412 patients, the use of surveillance techniques detected recurrence in 80% of patients with the following evaluations: examination (15%), imaging (27%), CA125 level (23%), and CA125 level and imaging in (35%). However, the authors did not find a difference in survival, regardless of
### TABLE 3
Ovarian cancer surveillance recommendations

<table>
<thead>
<tr>
<th>Variable</th>
<th>Months</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-12</td>
<td>12-24</td>
</tr>
<tr>
<td>Review of symptoms and physical examination</td>
<td>Every 3 mo</td>
<td>Every 3 mo</td>
</tr>
<tr>
<td>Papanicolaou test/ cytologic evidence</td>
<td>Not indicated</td>
<td>Not indicated</td>
</tr>
<tr>
<td>Cancer antigen 125</td>
<td>Optional</td>
<td>Optional</td>
</tr>
<tr>
<td>Radiographic imaging (chest X-ray, positron emission tomography/ computed tomography, magnetic resonance imaging)</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
</tr>
<tr>
<td>Recurrence suspected</td>
<td>Computed tomography and/or positron emission tomography scan</td>
<td>Computed tomography and/or positron emission tomography scan</td>
</tr>
<tr>
<td>Cancer antigen 125</td>
<td>Cancer antigen 125</td>
<td>Cancer antigen 125</td>
</tr>
</tbody>
</table>

* May be followed by a generalist or gynecologic oncologist.


the modality that was used.\(^{50}\) Ideally, prospective studies will help to determine the true role of interval CT scans in ovarian cancer surveillance.

Because CT scans may lack the ability to detect a small volume of disease, other imaging modalities have been reviewed. The use of magnetic resonance imaging has also been evaluated for its role in ovarian cancer surveillance. Although sensitivity ranges from 62-91% and specificity ranges from 40-100%, comparable detection rates to CT scans and increased costs have limited its generalized acceptance.\(^{41}\) Ultrasound scanning has also been investigated for ovarian cancer surveillance. Studies have shown sensitivity that ranged from 45-85% and specificity that ranged from 60-100%.\(^{41}\) However, because of user variability and limited visibility, this modality typically is not used for the evaluation of recurrent disease.

More recently, the use of PET-CT scans has been reported. Sensitivity varies from 45-100% and specificity ranges from 40-100%, although diagnostic accuracy rates approach as high as 95%.\(^{41,42,51}\) In patients with normal CA125 levels and clinical suspicion of disease (based on symptoms or surveillance CT scans), PET-CT was slightly more sensitive than CT scans for the detection of recurrent disease.\(^{52}\) Studies have shown that PET-CT will alter treatment in approximately 60% of patients with recurrent disease and may recommend PET-CT before secondary cytoreduction.\(^{53}\) However, the potential use of this modality for surveillance is limited, and currently the role of radiographic imaging is best reserved as a supplement to abnormalities in physical examination, CA125 levels, or symptoms.

Although improvements in primary treatment of ovarian cancer have occurred, outcomes after recurrence remain disappointing. Many physicians hypothesize that the detection of recurrence early potentially may improve the benefit of available treatments, especially surgery. Second-line therapies are rarely curative and often result in short-term progression-free survival. However, some patients, especially those who are good candidates for secondary surgical cytoreduction and/or those who remain platinum sensitive will have high response rates to salvage treatments. Until the ideal surveillance is determined, individualized patient plans that consist of a thorough assessment of symptoms and physical examination, which includes a pelvic examination, should be undertaken. The role for CA125 level monitoring should be discussed with patients. The pros and cons of imaging should be discussed with the patients who do not have an elevated CA125 level at the time of diagnosis. When a recurrence is suspected based on symptoms, examination, or CA125 level, a CT scan of the chest, abdomen, and pelvis should be obtained to determine the extent of the disease. PET scans are a useful adjunct when CT scans are indeterminate (Table 3).\(^{54}\)

**Low malignant potential (LMP) tumors**

Tumors of LMP, also called borderline tumors, account for 10-20% of epithelial ovarian tumors; approximately 4000 cases are diagnosed annually.\(^{55}\) The average age of a woman at the time of diagnosis is 40-60 years, but a significant proportion of these tumors occur in women in their child-bearing years.\(^{55}\) In general, the prognosis for women with LMP tumors is quite good, and most women (especially those with stage I disease) are at a very low risk of recurrence.\(^{2,5}\) Recurrences tend to occur late, and, even in advanced stages, 70% of recurrences will be after 5 years, and 30% will be after 10
years. Many patients with recurrent LMP tumors can be salvaged with additional surgery, and <5% eventually progress to invasive cancers.35-37

Current NCCN guidelines recommend physical examination, including pelvic examinations, CA125 level (if initially elevated), every 3-6 months and pelvic ultrasound scans for those women with fertility-sparing surgery. Complete hysterectomy with bilateral salpingo-oophorectomy is recommended once fertility is completed.37 However, there are no studies that suggest that this aggressive surveillance improves prognosis for women with LMP tumors.

Retrospective studies suggest that, in women who have undergone a complete hysterectomy with bilateral salpingo-oophorectomy and resection of all gross disease, surveillance should be similar that used for those women with invasive ovarian cancer. For patients who have undergone fertility-sparing surgery, either a unilateral salpingo-oophorectomy or a cystectomy, the risk of recurrence ranges from 7-30%.38 Current surveillance recommendations for women who have undergone fertility-preserving surgery are to undergo serial pelvic sonography because this is the most sensitive method of detection of recurrent disease in residual ovary.39 Ultrasound scanning with or without tumor markers is recommended on an every 6-month basis.

When recurrent disease is suspected, a CT scan of abdomen and pelvis is recommended to assess the extent of the disease. Because most women with LMP tumors can be salvaged with additional surgery,35 prompt attention to symptoms or physical examination abnormalities is important; however, there is no evidence that routine radiographic surveillance with CT scans is at all beneficial.

Germ cell and sex-cord stromal tumors of the ovary
Malignant germ cell tumors of the ovary are rare and account for 2.6% of all ovarian cancers.60 Most patients have abdominal pain and a palpable mass. Malignant germ cell tumors can produce serum tumor markers that can prove helpful in the diagnosis and posttreatment surveillance if they are elevated at the time of diagnosis. Alpha-fetoprotein can be produced by yolk sac tumors, embryonal carcinomas, polyembryomas, and immature teratomas. Human chorionic gonadotropin can be produced by choriocarcinomas, embryonal carcinomas, polyembryomas, and, in low levels, in some dysgerminomas. Lactate dehydrogenase can be a marker for dysgerminoma.61-63 Because these tumors tend to occur in young women and most are unilateral, fertility-sparing surgery has been used to include pelvic washings, unilateral salpingo-oophorectomy, peritoneal biopsies, omentectomy, and pelvic and paraaortic lymph node dissection. NCCN guidelines recommend observation for low-risk tumors such as stage I dysgerminomas and stage IA, grade 1 immature teratomas.57,61-63 All other malignant ovarian germ cell tumors in this country receive postoperative chemotherapy with bleomycin, etoposide, and platinum with excellent survival rates. However, in Europe some healthcare providers advocate observation of all stage I germ cell tumors.

Sex cord stromal tumors are rare and account for 1.2% of ovarian cancers.60 Sex cord stromal tumors of the ovary can also produce serum tumor markers such as estradiol, inhibin, Mullerian inhibitory substance, and testosterone.63,64 Granulosa cell tumors also have the possibility of late recurrence of disease, with a reported median time to recurrence of 4-6 years.62 Pelvic recurrence accounts for 30-45% of cases.64,65 Surveillance should include a thorough physical examination and serum tumor markers for an extended period of time because of reports of recurrence even 20 years after the initial diagnosis. The utility of imaging in sex-cord stromal tumors has not been proven, so imaging should be limited to patients with symptoms or concerning findings on physical examination.64,65

Studies that have evaluated surveillance strategies for ovarian germ cell tumors and sex cord stromal tumors have not been performed; therefore, recommendations are based on expert opinion. NCCN guidelines for surveillance recommend tumor markers every 2-4 months for 2 years if the markers were elevated originally. Physical examination that includes bimanual examination may be less helpful than serum tumor markers, especially in adolescent patients. Although recurrences are rare and data about them in the gynecologic oncology literature are small in number, they typically occur in the first 2 years after treatment. Although prognosis for recurrent germ cell tumors is usually poor, there are potentially curative treatment options that are available with multiagent chemotherapy regimens and high-dose chemotherapy with autologous stem cell support. Recently, the American Society of Clinical Oncology issued guidelines for surveillance using serum tumor markers for men with testicular cancer.66 The recommendations were similar to the current NCCN guidelines for germ cell tumors of the ovary in the first 2 years, with the exception that the surveillance continues for 10 years after treatment because of a reported incidence of 50% of the recurrences occurring 5 years after treatment in men.66 The timing of surveillance imaging in ovarian germ cell tumors is less well-characterized. NCCN guidelines for germ cell testicular tumors recommend CT scans every 3-6 months for the first 2 years then every 6-12 months until 6 years after treatment for those who received chemotherapy alone.67 Because germ cell tumors of the ovary occur in young women, because serum tumor markers are very sensitive for the presence of disease, and because repeated CT scans can lead to significant radiation exposure over time, the argument could be made that imaging is not indicated without evidence of the elevation of serum tumor markers, clinical symptoms, or concerning findings on physical examination. In addition, in those patients without elevated tumor markers, radiologic assessment in the first 2 years can be helpful (Table 4).

Cervical cancer
More than 12,000 women are diagnosed with cervical cancer each year in the United States.1 Patients are diagnosed with stage I disease in 50% of cases, and the 5-year survival rate for this group ex-
### TABLE 4
Nonepithelial ovarian cancer (germ cell and sex-cord stromal tumors) surveillance recommendations

<table>
<thead>
<tr>
<th>Variable</th>
<th>Months</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-12</td>
<td>12-24</td>
</tr>
<tr>
<td>Review of symptoms and physical examination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germ cell tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
</tr>
<tr>
<td>Sex-cord stromal tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
</tr>
<tr>
<td>Serum tumor markers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germ cell tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
</tr>
<tr>
<td>Sex-cord stromal tumors</td>
<td>Every 2-4 mo</td>
<td>Every 6 mo</td>
</tr>
<tr>
<td>Radiographic imaging (chest x-ray, computed tomography, magnetic resonance imaging)</td>
<td>Not indicated unless tumor marker normal at initial presentation</td>
<td>Not indicated unless tumor marker normal at initial presentation</td>
</tr>
<tr>
<td>Germ cell tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex-cord stromal tumors</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
</tr>
<tr>
<td>Recurrence suspected</td>
<td>Computed tomography scan</td>
<td>Computed tomography scan</td>
</tr>
<tr>
<td>Tumor markers</td>
<td>Tumor markers</td>
<td>Tumor markers</td>
</tr>
</tbody>
</table>


ceeds 90%. However, recurrence rates for this group of patients are high, ranging from 10–20%. The treatment of recurrent cervical cancer depends greatly on the primary therapy that is used and the location of recurrence. Patients with locally recurrent disease can be offered salvage treatments with the potential for cure. Distant metastases are rarely salvageable. In efforts to detect disease at curable states, surveillance has been advocated in patients who have successfully completed primary treatment.

Typically, more than three-fourths of recurrences will occur within the first 2-3 years after the initial treatment, which suggests a role for increased surveillance during this time frame. Thus, the NCCN guidelines recommend follow-up evaluation every 3-6 months for the first 2 years, followed by every 6 months for the next 3 years. These recommendations include cytologic evaluation at each visit and recommend annual chest radiographs, although optional. Use of other imaging is advocated on the basis of clinical indications. Similarly to most cancer surveillance, these recommendations are based on retrospective studies.

Although patients are often observed every 3-4 months during the first 2 years, recurrence is diagnosed during routine follow-up examination in few cases, ranging from 26–36% of cases. Despite surveillance, presentation with symptoms is common, ranging from 46–95% of patients. These symptoms often include abdominal and pelvic pain, leg symptoms such as pain or lymphedema, vaginal bleeding or discharge, urinary symptoms, cough, and weight loss. Additionally, the presence of symptoms or suspicion of recurrence prompted unscheduled evaluation in approximately 40% of patients. Thus, counseling patients about signs and symptoms remains an important part of survivorship care.

The use of physical examination for cervical cancer surveillance has been well accepted. In a review, this simple method accounted for the highest rate of asymptomatic disease, ranging from 29–75%. Physical examination accounted for the highest detection rate when compared with cytologic evaluation and imaging modalities. The evaluation should include a complete assessment of areas that are susceptible to the human papilloma virus and a thorough speculum, bimanual, and rectovaginal examination. Although there is insufficient evidence in cancer surveillance, cytologic evaluation may have value in the detection of other lower genital tract neoplasia. Along with symptoms, physical examination will detect most cases of recurrent cervical cancer.

In efforts to detect patients with a vaginal/local recurrence, surveillance with cytologic evaluation has been recommended. Unfortunately, retrospective studies have shown cytologic evaluation to be consistently low yield, with detection rates that range from 0–17%. In addition, other studies have found that rarely was cytologic evidence the only abnormality and that clinical ev-
idence of disease was often or soon thereafter apparent. These low rates of detection have led to the recommendations by authors to eliminate the use of cytologic evaluation or to limit its use to once a year. Furthermore, the role of cytologic evaluation in patients who have undergone pelvic radiation therapy may be limited, and the elimination of its use from routine surveillance may be acceptable. Thus, the reduction of unnecessary cytologic evaluation may provide an opportunity for significant cost-savings while maintaining quality of care in these patients.

Imaging has also been suggested for surveillance in the asymptomatic patient. In regards to chest radiographs, rates of detection range from 20–47%. Because of a higher distant failure rate, Salmal et al advocated its use, particularly in patients who had received radiotherapy. However, because many of these cases are not salvageable, others have questioned its use. Although some studies have reported successful treatments for patients with isolated pulmonary recurrence, there is little evidence to support its use at this time. Other studies have evaluated the use of radiographic imaging modalities (such as CT scan and magnetic resonance imaging), pelvic ultrasound scans, and intravenous pyelograms. Unfortunately, the rates of detection are low, and these tests have not proven useful for routine surveillance. However, these tests may be indicated based on patient symptoms or findings on examination, and their use should be individualized.

PET ± CT scans have also been used for the evaluation of recurrent cervical cancer. In patients with clinical suspicion of recurrence, PET scans detected disease with high sensitivity (86%) and specificity (87%). More recently, its use as a surveillance tool has been studied with promising results. In this series, PET–CT showed locoregional disease in 8 of the 9 asymptomatic patients, compared with 4 of the 21 with symptoms that were being evaluated. Because pelvic recurrences may be amenable to salvage therapy, with radiation or exenteration, this modality may have potential benefit; further investigations are ongoing.

One of the major components of surveillance is its ability to impact survival. Survival for women with recurrent cervical cancer has been assessed only in retrospective analyses, which compare those women with or without symptoms at the time recurrence is diagnosed. Median survival rates in asymptomatic and symptomatic patients ranged from 8–53 months and 8–38 months, respectively. Several studies have reported improved median survival in patients who were detected with asymptomatic recurrence, regardless of the method of diagnosis, and advocate the need for surveillance programs. Other reports have noted similar survival regardless of symptoms and have questioned the effectiveness of routine surveillance.

Surveillance should be focused on recurrent disease that is amenable to treatment and that will result in cure or long-term survival. Unfortunately, in regards to cervical cancer, this is limited predominantly to locoregional recurrence. The potential of newer modalities, which includes PET/CT scanning, must be investigated further in prospective studies, especially given the high cost. However, only retrospective data are available, history and physical examination are the only consistent methods that have been reported for the detection of recurrence; and specific follow-up plans should be discussed with patients. If recurrent disease is suspected based on symptoms or examination, a CT scan of the chest, abdomen, and pelvis is recommended to evaluate the extent of disease, and a biopsy should be obtained to confirm recurrence. PET/CT scanning is usually performed before definitive radiation or exenterative surgery to identify distant disease that would alter management (Table 5).

**Vulvar cancer**

With 3900 new cases and 920 deaths annually in the United States, vulvar cancer is uncommon and represents approximately 4% of malignancies of the female genital tract and 0.6% of all cancers in women. Radical local excision of the vulva and inguinofemoral lymphadenectomy has been the standard surgical therapy for nearly 8 decades. More recent advances have led to the introduction of preoperative chemoradiation for large primary tumors that involve the urethra, vagina, or anus and the investigation of the sentinel lymph node technique. Survival of patients with vulvar cancer correlates with International Federation of Gynecology and Obstetrics stage. The prognosis for patients with early-stage disease is generally good. Lymph node status is the single most important prognostic factor. Patients with negative lymph nodes have a 5–year survival rate of >80%, which falls to <50% for patients with positive lymph nodes and to as low as 13% for those with ≥4 positive nodes. Although patients with local recurrences may be salvageable, groin or distant recurrences generally are fatal.

There is no direct evidence to inform surveillance strategies for patients with vulvar cancer after definitive treatment. There are no NCCN practice guidelines to address this issue. Thus, surveillance strategies for patients with definitively treated vulvar cancer are extrapolated from other disease sites, mainly cervix cancer. A report from the Mayo Clinic on 330 patients with primary squamous cell carcinoma of the vulva, >95% of whom underwent bilateral inguinofemoral lymphadenectomy, underscores the significant correlation between lymph node status and the risk of treatment failure in the first 2 years after initial therapy; 44.2% overall recurrence rate with positive vs 17.5% with negative lymph nodes. After 2 years, patients with positive and patients with negative nodes had similar recurrence rates. Importantly, more than one-third of relapses occurred ≥5 years after the initial therapy. In other words, nearly 1 in 10 patients had a late (>5 years) reoccurrence of disease (same site recurrence or second primary vulvar site), which demonstrates the need for long-term surveillance. More than 95% of those late relapses had local recurrences; 13% of the relapses also demonstrated evidence of distant disease. This pattern of predominantly local recurrence is confirmed by another study of 399 patients with node-negative...
TABLE 5
Cervical, vulvar, and vaginal cancer surveillance recommendations

<table>
<thead>
<tr>
<th>Variable</th>
<th>Months</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review of symptoms and physical examination</td>
<td>0-12</td>
<td>3-5</td>
</tr>
<tr>
<td>Low risk (early stage, treated with surgery alone, no adjuvant therapy)</td>
<td>Every 6 mo</td>
<td>Yearly</td>
</tr>
<tr>
<td>High risk (advanced stage, treated with primary chemotherapy/</td>
<td>Every 3 mo</td>
<td>Every 6 mo</td>
</tr>
<tr>
<td>radiation therapy or surgery plus adjuvant therapy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papanicolaou test/cytologic evidence</td>
<td>Yearly</td>
<td>Yearly</td>
</tr>
<tr>
<td>Routine radiographic imaging (chest x-ray, positron emission tomography</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
</tr>
<tr>
<td>computed tomography, magnetic resonance imaging)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrence suspected</td>
<td>Computed tomography and/or positron emission tomography scan</td>
<td>Computed tomography and/or positron emission tomography scan</td>
</tr>
</tbody>
</table>

* May be followed by a generalist or gynecologic oncologist. ** Insufficient evidence for cancer recurrence but may have value in the detection of other lower genital tract neoplasia.


squamous cell carcinoma of the vulva, 23% of which recurred with >90% of the recurrences in the vulva.54

Because of the propensity for local recurrence (regular and long-term), careful evaluations of the vulva and groin constitute the cornerstone of posttreatment surveillance for these patients. This should include careful visual inspection of the vulva, skin bridge, and inguinal lymph nodes. Because a significant number of vulvar cancers are human papillomavirus associated, such examination should survey not only for vulvar recurrence or multifocal vulvar cancer but also for cervical, vaginal, and perianal neoplasia. Whether asymptomatic patients with positive groin nodes benefit from additional imaging for the assessment of distant sites of failure is unproven and generally not recommended because salvage therapies are relative ineffective. Patients whose symptoms or review of systems suggests the possibility for distant failure should undergo additional imaging and may be evaluated similarly as with patients with cervical cancer. If exenterative surgery is considered for local recurrence, PET-CT should be performed to rule out distant disease that would alter management (Table 5).54

Vaginal cancer
Primary cancer of the vagina is an uncommon malignancy. With approximately 2300 cases diagnosed annually in the United States, vaginal cancer comprises approximately 3% of all malignant neoplasms of the female genital tract.1 Given the rarity of the disease, there is a paucity of information to guide posttreatment surveillance for patients with vaginal cancer. There are no data to support the routine use of follow-up vaginal cytologic evaluation or imaging in the asymptomatic patient. Posttreatment surveillance relies primarily on the careful assessment of symptoms and physical examination, which should survey not only for vaginal recurrence or multifocal vaginal cancer but also for cervical, vul-

var, and perianal neoplasia. Patients with a suspicion of recurrent disease should undergo additional imaging for the evaluation of disease extent that may help guide treatment options (Table 5).85

Comment
Although gynecologic cancers account for only 10% of all new cancer cases in women, the number of survivors from these malignancies approaches 20%.1,86 Improvements in cancer care have resulted in almost 10 million cancer survivors, and this number is expected to grow at an even faster rate than ever before.86 Thus, the determination of the most clinically and cost-effective surveillance for the detection of recurrence is critical.

As survivorship increases, transitioning patients from oncology care to the primary care setting is becoming a common practice. However, this shift results in the burden of care falling on primary care providers who may not be comfortable or trained to deal with follow-up
needs or practice standards for patients with cancer. Although the Institute of Medicine’s report advocates for open communication between oncologists and primary care providers, almost 50% of primary care physicians did not feel comfortable with cancer surveillance and standard guidelines for cancer recurrence. However, primary care providers generally are willing to assume cancer follow-up care, typically after 2 years from treatment. In a survey, primary care providers believed the transition of oncology patients could be improved with an individualized treatment summary, guidelines for surveillance, and expedited routes of referral for suspected recurrence. Thus, the provision of up-to-date information and the education of both patients and physicians are mandatory.

However, a recent evaluation of cancer survivorship care demonstrated a significant discordance among primary care providers, oncologists, and patients. This discrepancy was seen with primary cancer surveillance and with the recommendation of cancer screening and preventative healthcare management. Therefore, it is important not only to specify routine cancer surveillance but also to continue routine screening guidelines in cancer survivors and to promote healthy behaviors. As rates of the development of a second cancer approach 10% within 30 years, communication between providers and with patients will improve adherence to guidelines and reduce repetitive testing. Despite its association with cancer and comorbidities, almost one-quarter of cancer survivors continue to use tobacco after the first year of diagnosis; rates, which exceed 37%, are highest in patients with a history of gynecologic malignancies. Thus, both oncologists and primary care providers should advocate for smoking cessation in these patients. In addition, the promotion of exercise and weight reduction (if indicated), of the monitoring of bone density, and of breast and colorectal screening is important.

If not previously done, the surveillance period may provide an opportunity to assess patients who are at a higher risk for cancer than the general popula-

FIGURE

Checklist for surveillance of gynecologic malignancies

| Patient name |  
| Visit date |  
| Disease site and stage |  
| Date of diagnosis/surgery |  
| Date treatment completed |  

Symptoms review and treatment side-effects

- Pain (abdominal or pelvic, hip or back)
- Abdominal bloating
- Vaginal bleeding (also rectum, bladder)
- Weight loss
- Nausea and/or vomiting
- Cough or shortness of breath
- Lethargy/fatigue
- Swelling of abdomen or leg(s)
- Depression
- Sexual dysfunction
- Neuropathy
- Fatigue

Physical examination

- General physical examination targeted to symptoms
- Lymph node assessment (axillary, supraclavicular, and inguinal)
- Pelvic examination (evaluation of lower genital tract, speculum, bimanual, rectovaginal examination)

Laboratory

- Tumor markers

Disease status

- No evidence of disease
- Suspect recurrence
  - Radiographic imaging
  - Biopsy
- Refer to gynecologic oncologist

Routine health maintenance

Breast cancer screening

- Yearly clinical breast examination
- Mammogram

Every 1-2 years starting with ages 40-49 years, then yearly

Colon cancer screening

- Colonoscopy or flexible sigmoidoscopy

Every 5-10 years beginning at age 50 years

Genetic screening

- Not indicated
- Recommended/completed

Consider if patient is diagnosed at a young age, strong family history, multiple primaries (see specific surveillance guidelines)

Menopausal assessment

Osteoporosis prevention

- Calcium (1200-1500 mg) and vitamin D (800 IU)
- Bone mineral density testing

Begin at age 65 years (sooner if high risk factors)

Smoking cessation

Weight maintenance (exercise, diet)

tion. Obtaining a thorough personal and family history, which would include cancer type and age at diagnosis, may help to identify patients who are at risk and result in a referral to genetic counseling for additional assessment. Furthermore, patients and family members with a known or suspected genetic predisposition may require a more intensive screening program. Improving one’s awareness of risk will enhance compliance with these recommendations and ultimately decrease preventable cancers.90

The goal of follow-up evaluation for the detection of recurrent disease requires both clinical and cost-effectiveness. Failure to adhere to recommended guidelines results in unnecessary tests, and efforts should be made to provide effective surveillance, which will result in cost-savings.86-91 Currently, the ideal tests and schedule for gynecologic cancer surveillance have not yet been established; however, a detailed review of symptoms and physical examination at each visit results in the detection of most recurrences (Figure). The use of additional modalities has not been well-supported; and individualized treatment plans should be made with each patient. The lack of evidence-based guidelines for surveillance can be addressed only with prospective studies; the incorporation of cost-effective follow-up plans into the design of clinical trials will help to establish the ideal regimens.

ACKNOWLEDGMENT

The Society of Gynecologic Oncologists’ (SGO) Clinical Practice Committee has developed a series of Clinical Documents that are designed in part to improve the overall quality of women’s cancer care, to reduce the use of unnecessary, ineffective, or harmful interventions, and to facilitate the treatment of patients with a goal to maximum the chance of benefit with a minimum risk of harm and at an acceptable cost. SGO Clinical Documents remain strictly confidential and are not to be disclosed or disseminated by any participant in the process before the Document’s publication.

SGO Clinical Documents may have direct impact on the practice of treating women with gynecologic malignancies.

Clinical Documents are intended to be educational devices that provide information that may assist healthcare providers in caring for patients. This Clinical Document is not a rule and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment. Clinical Documents are not intended to supplant the judgment of the healthcare provider with respect to particular patients or special clinical situations. Clinical decisions in any particular case involve a complex analysis of a patient’s condition and available courses of action with the ultimate determination to be made by the healthcare provider in light of each individual patient’s circumstances. Therefore, clinical considerations may lead a healthcare provider to take a course of action appropriately that varies from this Document.

This Clinical Document has met SGO’s criteria of an Expert Clinical Opinion Document.

REFERENCES

74. Bodurka-Beavers D, Morris M, Eiel PJ, et al. Posttherapy surveillance of women with cervi-